PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
J Clin Oncol. 2024;:JCO2400003 - PMID: 39298718 - DOI: 10.1200/JCO.24.00003
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Cancer Biomark. 2024;41(1):83-91 - PMID: 39269823 - DOI: 10.3233/CBM-230431
Cancer tissue of origin constrains the growth and metabolism of metastases.
Nat Metab. 2024;6(9):1668-1681 - PMID: 39160333 - DOI: 10.1038/s42255-024-01105-9
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2024;11:455-461 - PMID: 38463542 - PMCID: PMC10921889 - DOI: 10.2147/JHC.S452564
Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.
Cancer Immunol Res. 2024;12(4):400-412 - PMID: 38260999 - PMCID: PMC10985468 - DOI: 10.1158/2326-6066.CIR-23-0486
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer.
Radiother Oncol. 2024;192:110091 - PMID: 38224917 - PMCID: PMC10905770 - DOI: 10.1016/j.radonc.2024.110091
9